XKRX137310
Market cap882mUSD
Dec 24, Last price
10,510.00KRW
1D
-1.13%
1Q
12.65%
IPO
-82.22%
Name
SD Biosensor Inc
Chart & Performance
P/E
—
P/S
1.96
EPS
—
Div Yield, %
2.30%
Shrs. gr., 5y
1.53%
Rev. gr., 5y
58.46%
Revenues
655.68b
-77.64%
Net income
-467.71b
L
CFO
-242.32b
L
Dividend
Dec 27, 2023290 KRW/sh
Profile
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 655,676,513 -77.64% | 2,932,001,440 0.07% | 2,929,960,840 73.76% | |||
Cost of revenue | 708,506,983 | 1,673,064,336 | 1,507,505,942 | |||
Unusual Expense (Income) | ||||||
NOPBT | (52,830,470) | 1,258,937,104 | 1,422,454,898 | |||
NOPBT Margin | 42.94% | 48.55% | ||||
Operating Taxes | 29,290,121 | 333,299,788 | 376,384,935 | |||
Tax Rate | 26.47% | 26.46% | ||||
NOPAT | (82,120,590) | 925,637,316 | 1,046,069,962 | |||
Net income | (467,711,537) -151.32% | 911,362,364 -16.27% | 1,088,470,714 76.80% | |||
Dividends | (29,549,598) | (198,735,120) | (49,924,925) | |||
Dividend yield | 2.33% | 6.51% | 0.92% | |||
Proceeds from repurchase of equity | 227,604,471 | 2,383,016 | 407,828,084 | |||
BB yield | -17.95% | -0.08% | -7.48% | |||
| Debt | ||||||
Debt current | 136,420,355 | 13,057,235 | 6,590,277 | |||
Long-term debt | 480,265,305 | 35,917,554 | 43,071,520 | |||
Deferred revenue | 60,575 | |||||
Other long-term liabilities | 21,738,951 | 6,427,929 | 3,476,886 | |||
Net debt | (153,207,194) | (1,898,462,608) | (902,617,829) | |||
| Cash flow | ||||||
Cash from operating activities | (242,318,513) | 890,233,363 | 1,234,945,051 | |||
CAPEX | (142,565,918) | (300,451,246) | (99,293,783) | |||
Cash from investing activities | (1,912,528,505) | 358,519,312 | (957,730,681) | |||
Cash from financing activities | 769,762,101 | (225,736,837) | 351,263,798 | |||
FCF | (230,864,896) | 500,758,618 | 1,095,647,475 | |||
| Balance | ||||||
Cash | 557,717,346 | 2,069,971,206 | 1,895,498,700 | |||
Long term investments | 212,175,508 | (122,533,808) | (943,219,074) | |||
Excess cash | 737,109,028 | 1,800,837,326 | 805,781,584 | |||
Stockholders' equity | 1,983,073,406 | 2,448,188,180 | 1,728,479,955 | |||
Invested Capital | 2,720,190,396 | 985,850,148 | 1,073,608,499 | |||
ROIC | 89.89% | 134.92% | ||||
ROCE | 45.18% | 75.69% | ||||
| EV | ||||||
Common stock shares outstanding | 110,860 | 101,299 | 97,521 | |||
Price | 11,440.00 -62.06% | 30,150.00 -46.06% | 55,900.00 | |||
Market cap | 1,268,234,568 -58.48% | 3,054,162,709 -43.98% | 5,451,432,620 | |||
EV | 1,122,914,024 | 1,158,179,984 | 4,561,672,591 | |||
EBITDA | 84,710,730 | 1,299,757,005 | 1,441,569,575 | |||
EV/EBITDA | 13.26 | 0.89 | 3.16 | |||
Interest | 49,227,537 | 994,059 | 488,655 | |||
Interest/NOPBT | 0.08% | 0.03% | ||||